Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2018 Mar-Apr;56(2):180-185.

Gene signatures for breast cancer, clinical utility and therapeutic applications

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 17, Servicio de Planificación Familiar. Ciudad de México, México


in English, Spanish

Gene signatures quantify hormone receptors and proliferation genes, combining multivariate prediction models. Hormone-negative tumors have greater proliferation and the prognostic value is limited. The first generation of prognostic signatures (Oncotype DX, MammaPrint, Genomic Degree Index) predict recurrence at 5 years. Subsequent tests (Prosigna, EndoPredict, Breast Cancer Index) have better prognostic value for recurrence and are predictive of early relapse. There are no useful prognostic genetic tests for hormone-negative tumors, or predictors of response to treatment. The recent expansion of high-performance technology platforms including the low-cost sequencing of tumor-derived DNA and circulating RNA and the reliable rapid quantification of microRNAs offer new opportunities to build prediction models.


Breast Neoplasms; Chemotherapy, Adjuvant; Oncogenes

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center